Cancer Harboring BRAF Alterations clinical trials at UCLA

1 research study open to eligible people

FORE8394 in Participants With Cancer Harboring BRAF Alterations
open to eligible people ages 8 years and up
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors, including rare BRAF V600E-mutated solid tumors, including anaplastic thyroid, ovarian, cholangiocarcinoma or other rare cancers.
Westwood, Los Angeles, California and other locations

Last updated: July 23, 2026

FORE8394 in Participants With Cancer Harboring BRAF Alterations